Bio-Path (NASDAQ:BPTH) Coverage Initiated at Wall Street Zen

Investment analysts at Wall Street Zen started coverage on shares of Bio-Path (NASDAQ:BPTH) in a note issued to investors on Wednesday. The firm set a “sell” rating on the stock.

Bio-Path Stock Up 3.5%

NASDAQ BPTH opened at $0.18 on Wednesday. Bio-Path has a twelve month low of $0.12 and a twelve month high of $4.55. The stock has a 50-day moving average of $0.16 and a 200 day moving average of $0.53.

About Bio-Path

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.